NASDAQ · Biotechnology

enGene Therapeutics Inc. (ENGN) Stock

$1.78 +2.01% NASDAQ: ENGN Healthcare

Valuation

MetricValue
Price$1.78
Market Cap$119.24M
P/E Ratio-6.93
P/B Ratio0.59
P/S Ratio0.00
EPS (TTM)$-2.29
52-Week High$12.25
52-Week Low$1.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2.10%
ROA-1.70%
ROCE-1.79%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.14
Current Ratio6.28

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-16.0M$-19.0M$-26.0M$-62.0M$-123.0M
Net Profit$-23.0M$-24.0M$-100.0M$-55.0M$-117.0M
EPS$-0.01$-1.84$-4.24$-1.46$-2.29
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$131.0M$132.0M$87.0M$311.0M$221.0M
Total Liabilities$4.0M$5.0M$14.0M$39.0M$54.0M
Cash$1.0M$0$82.0M$173.0M$50.0M
Borrowings$4.0M$32.0M$10.0M$25.0M$32.0M

Latest News

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones Business Wire · Jul 16, 2026 Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman GlobeNewswire · Jul 15, 2026 Sector Update: Healthcare Stocks Decline Late Afternoon MT Newswires · Jun 18, 2026 Neumora depression drug fails; EnGene to cut 50% of staff BioPharma Dive · Jun 16, 2026 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-18.0M$-25.0M$-48.0M$-99.0M
Investing Cash Flow$0$0$-1.0M$-127.0M$-27.0M
Financing Cash Flow$0$0$-4.0M$-7.0M$0
Net Cash Flow$6.0M$9.0M$61.0M$91.0M$-123.0M
Free Cash Flow$-16.0M$-18.0M$-25.0M$-49.0M$-101.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-0.93
FCF Yield-80.02%
Quick Ratio10.21
Interest Coverage-1.53
Return 1Y-46.58%
Return 3Y-82.57%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About enGene Therapeutics Inc.

enGene Therapeutics Inc. is led by CEO Ronald H. W. Cooper, employs 56 people, headquartered in CA, publicly traded since 2022.

enGene Therapeutics Inc. (ENGN) stock trades at $1.78 with a market capitalization of $119.24M. The stock is valued at a price-to-earnings (P/E) ratio of -6.93, price-to-book of 0.59, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.40 and $12.25, and currently trades 85.5% below its 52-week high.

On profitability, enGene Therapeutics Inc. generates a return on equity (ROE) of -2.10%, return on capital employed of -1.79%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides